These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34060947)

  • 1. Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.
    MacArthur TA; Fahy AS; Jakub JW
    Am Surg; 2021 Jun; 87(6):849-854. PubMed ID: 34060947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
    Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
    J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
    Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS
    Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
    Hsu AC; Kokot NC; Eisenberg BL; Thomas JS
    Oral Oncol; 2020 Dec; 111():104899. PubMed ID: 32665184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC).
    Mulder EEAP; Stahlie EHA; Verver D; Lemstra C; Been LB; Mooyaart AL; Brabander T; Vegt E; Verburg FA; van der Veldt AAM; Verhoef C; van Akkooi ACJ; Grünhagen DJ
    J Surg Oncol; 2021 Dec; 124(7):1161-1165. PubMed ID: 34235758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary Experience.
    Burke LMB; Yu H; Burke K; Gwynn M; Louie RJ; Ollila DW; Rn PL; Collichio F
    Cardiovasc Intervent Radiol; 2021 May; 44(5):801-806. PubMed ID: 33447922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
    Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
    Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma.
    Henning A; Agnese D; Chung CG
    J Cutan Pathol; 2021 Nov; 48(11):1423-1426. PubMed ID: 34189749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
    Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM
    J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.
    Monga V; Miller BJ; Tanas M; Boukhar S; Allen B; Anderson C; Stephens L; Hartwig S; Varga S; Houtman J; Wang L; Zhang W; Jaber O; Thomason J; Kuehn D; Rajput M; Metz C; Zamba KD; Mott S; Abanonu C; Bhatia S; Milhem M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future Directions and Challenges Facing Intralesional Immunotherapy With Talimogene Laherparepvec for Advanced Melanoma.
    Queen D; Samie FH; Zeitouni NC
    Dermatol Surg; 2021 Jan; 47(1):132-133. PubMed ID: 31574028
    [No Abstract]   [Full Text] [Related]  

  • 14. Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy.
    Drescher C; Drexler K; Hilber H; Schmidt B; Haferkamp S
    J Dtsch Dermatol Ges; 2019 Mar; 17(3):321-323. PubMed ID: 30698924
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
    Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
    JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy.
    Casale F; Tchanque-Fossuo C; Stepenaskie S; Durkin J
    Dermatol Online J; 2022 Jan; 28(1):. PubMed ID: 35499413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
    Chitnis SD; Seim NB; Kendra K
    J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Talimogene Laherparepvec Use in Kidney Transplant Recipient.
    Gupta M; Brennan DC; Alhamad T
    Transplantation; 2020 Apr; 104(4):e109-e110. PubMed ID: 31815902
    [No Abstract]   [Full Text] [Related]  

  • 19. The histological spectrum of talimogene laherparepvec (TVEC) injections-Neutrophilic and chronic granulomatous dermatitis.
    Lee K; Pouldar D; Shiu J; Elsensohn A; de Feraudy S
    J Cutan Pathol; 2019 Feb; 46(2):165-167. PubMed ID: 30414194
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
    Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL
    J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.